Alembic Pharmaceuticals Receives FDA Tentative Approval for 400mg Bosutinib Cancer Treatment
核心洞察
Alembic Pharmaceuticals secured tentative FDA approval for its 400mg Bosutinib tablets, a kinase inhibitor used to treat Philadelphia chromosome-positive chronic myelogenous leukemia.
The approved product is therapeutically equivalent to Bosulif tablets marketed by PF Prism C.V., with an estimated US market size of $251 million for the twelve months ending September 2025.
This approval adds to Alembic's existing final FDA approvals for 100mg and 500mg Bosutinib tablets, bringing the company's total ANDA approvals to 232.
Alembic Pharmaceuticals Limited announced it has received tentative approval from the US Food and Drug Administration (FDA) for its supplemental Abbreviated New Drug Application (sANDA) for Bosutinib tablets, 400 mg. The approval represents a significant milestone for the Indian pharmaceutical company in expanding its oncology portfolio in the US market.
Therapeutic Profile and Market Opportunity
The approved product is therapeutically equivalent to Bosulif tablets, 400 mg, marketed by PF Prism C.V. Bosutinib is a kinase inhibitor indicated for the treatment of adult patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML). The drug addresses multiple patient populations, including newly-diagnosed patients and those who are resistant or intolerant to prior therapies. Additionally, it is indicated for treatment of patients with accelerated or blast phase Ph+ CML who have shown resistance or intolerance to earlier treatments.
According to IQVIA data, Bosutinib tablets, 400 mg, have an estimated market size of $251 million for the twelve months ending September 2025, highlighting the commercial potential of this approval.
Expanding Bosutinib Portfolio
This tentative approval complements Alembic's existing Bosutinib portfolio. The company had previously received final FDA approval for its ANDA Bosutinib tablets in 100 mg and 500 mg strengths. The addition of the 400 mg dosage represents an additional opportunity in the molecule's lifecycle, providing healthcare providers with more dosing flexibility for patient treatment.
Regulatory Achievement
With this latest approval, Alembic has achieved a cumulative total of 232 ANDA approvals from the US FDA, comprising 212 final approvals and 20 tentative approvals. This milestone underscores the company's consistent regulatory success and manufacturing capabilities in meeting FDA standards.
Company Background
Alembic Pharmaceuticals Limited is a vertically integrated research and development pharmaceutical company that has been operating in healthcare since 1907. Headquartered in India, the publicly listed company manufactures and markets generic pharmaceutical products globally, maintaining a strong presence in the competitive US generics market.